C92.11
Chronic myeloid leukemia, BCR/ABL-positive, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Chronic myeloid leukemia (CML) is a type of cancer that originates in the blood-forming cells of the bone marrow. When diagnosed as BCR/ABL-positive, it indicates the presence of a specific genetic abnormality crucial for diagnosis and treatment. The ICD-10 code C92.11 refers to CML that is currently in remission, meaning that signs and symptoms are reduced or absent following treatment. Staying informed about this condition helps patients understand their health status and the importance of ongoing medical care. CML progresses through phases, with the chronic phase being the initial stage where treatment tends to be most effective. Achieving remission signifies that the disease is under control, although ongoing monitoring remains essential for maintaining health and detecting any potential recurrence.
Causes & Symptoms
Clinical Causes: The primary cause of CML is a genetic mutation involving the Philadelphia chromosome, resulting from the translocation between chromosomes 9 and 22. This genetic abnormality leads to the creation of the BCR/ABL fusion gene, which produces an abnormal tyrosine kinase enzyme that promotes uncontrolled cell division. While the exact cause of the genetic mutation remains unknown, factors such as exposure to certain chemicals or radiation may increase risk. Genetic predisposition does not play a significant role, and CML is typically not inherited.
Key Symptoms: Fatigue or feeling unusually tired Unexplained weight loss Night sweats Fever without an apparent infection Abdominal discomfort or fullness due to an enlarged spleen Frequent infections or easy bruising Bone pain or tenderness Swelling of the lymph nodes
Diagnostic & Treatment
Diagnosis Path: Diagnosing CML involves several steps to identify the presence of abnormal blood cells and genetic markers: - **Blood Tests:** Complete blood count (CBC) revealing elevated white blood cell counts and other abnormalities. - **Bone Marrow Biopsy:** Examination of marrow tissue to assess cellularity and detect abnormal cells. - **Genetic Testing:** Detecting the BCR/ABL fusion gene through techniques such as PCR or FISH testing to confirm BCR/ABL positivity. - **Imaging:** Sometimes used to evaluate organ enlargement, particularly the spleen.
Treatment Protocols: While reaching remission is a significant milestone, ongoing management is necessary to maintain health and prevent relapse: - **Tyrosine Kinase Inhibitors (TKIs):** Medications such as imatinib, dasatinib, and nilotinib target the BCR/ABL fusion protein, controlling disease activity. - **Regular Monitoring:** Frequent blood tests and genetic assessments to detect any signs of disease recurrence. - **Supportive Care:** Managing symptoms, side effects, and maintaining overall well-being. - **Additional Therapies:** In some cases, stem cell transplants may be considered if the disease progresses or does not respond to medication. Patients in remission should continue with medical follow-up to ensure sustained control of the leukemia.
Clinical Advice & FAQs
Billing Guidance
Is C92.11 a billable ICD-10 code?
Yes, C92.11 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.11?
Clinical documentation must specify the nature of Chronic myeloid leukemia, BCR/ABL-positive, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference